MiR-210 as a Prognostic Marker in Breast Cancer
Author Information
Author(s): Rothé Françoise, Ignatiadis Michail, Chaboteaux Carole, Haibe-Kains Benjamin, Kheddoumi Naïma, Majjaj Samira, Badran Bassam, Fayyad-Kazan Hussein, Desmedt Christine, Harris Adrian L., Piccart Martine, Sotiriou Christos
Primary Institution: Translational Research Unit, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
Hypothesis
Can miRNA profiling improve the understanding of breast cancer biology and predict clinical outcomes?
Conclusion
MiR-210 expression is linked to tumor proliferation and is a strong potential biomarker of clinical outcome in breast cancer.
Supporting Evidence
- MiR-210 expression was associated with poor clinical outcomes in both ER-positive and ER-negative breast cancer patients.
- High levels of miR-210 were linked to increased tumor proliferation and invasion.
- MiR-210 showed similar prognostic performance to multi-gene signatures in breast cancer.
Takeaway
This study found that a tiny molecule called miR-210 can help doctors understand how aggressive a breast cancer might be and predict how well a patient will do.
Methodology
Global miRNA expression profiling using microarray technology was conducted in 56 untreated breast cancer patients, confirmed with qRT-PCR in an independent dataset of 89 ER-positive patients.
Limitations
The sample size is small, and results need further validation in larger cohorts.
Participant Demographics
Patients included 56 untreated breast cancer patients and 89 ER-positive patients treated with tamoxifen.
Statistical Information
P-Value
p=0.004 for ER-positive and p=0.008 for ER-negative populations
Confidence Interval
95% CI: 1.93–10.16
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website